Dyslipidaemia and cardiovascular risk in HIV infection.
Cardiovascular disease is increasingly recognised as a consequence of human immunodeficiency virus (HIV) infection in the era of highly active antiretroviral therapy (HAART). Dyslipidaemia is also a feature of HIV infection itself and the antiretroviral drugs from the protease inhibitor classes. Increased rates of atherosclerotic disease and diabetes have been associated with lipodystrophy and now from one of the major causes of morbidity in HIV and acquired immunodeficiency syndrome (AIDS).This review, based on a multi-database keyword search, summarises the lipid changes observed in the course of HIV infection and its treatment, and puts them into the context of other risk factors for cardiac disease, and other causes of cardiovascular disease in HIV.
Kulasekaram
Ranjababu
R
HIV Medicine, St. Thomas' Hospital, London, UK. ranjababu.kulasegaram@gstt.nhs.uk
Peters
Barry S
BS
Wierzbicki
Anthony S
AS
D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D008055:Lipids / Q000502:physiology; D012307:Risk Factors
D044966:Anti-Retroviral Agents; D001786:Blood Glucose; D008055:Lipids